Linda Sun

1.6k total citations
34 papers, 813 citations indexed

About

Linda Sun is a scholar working on Statistics and Probability, Oncology and Molecular Biology. According to data from OpenAlex, Linda Sun has authored 34 papers receiving a total of 813 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Statistics and Probability, 12 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Linda Sun's work include Statistical Methods in Clinical Trials (16 papers), Optimal Experimental Design Methods (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Linda Sun is often cited by papers focused on Statistical Methods in Clinical Trials (16 papers), Optimal Experimental Design Methods (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Linda Sun collaborates with scholars based in United States, South Korea and Canada. Linda Sun's co-authors include Justin L. Ricker, David S. Siegel, Kenneth C. Anderson, Stanley R. Frankel, Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, Bruce D. Cheson, Huafeng Xie and Sophia Randolph and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Linda Sun

31 papers receiving 795 citations

Peers

Countries citing papers authored by Linda Sun

Since Specialization

Citations

This map shows the geographic impact of Linda Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Sun more than expected).

Fields of papers citing papers by Linda Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Sun. The network helps show where Linda Sun may publish in the future.

Co-authorship network of co-authors of Linda Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Sun. A scholar is included among the top collaborators of Linda Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Sun. Linda Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjusted Inference for Multiple Testing Procedure in Group‐Sequential Designs 2024 ·Biometrical Journal ·Yujie Zhao, (unknown), Linda Sun, Keaven M. Anderson	0
2	Tumor-Agnostic Approvals: Insights and Practical Considerations 2023 ·Clinical Cancer Research ·(unknown), Robert A. Beckman, Xiaoyun Li, Weidong Zhang, (unknown), (unknown), Linda Sun, Hong Tian, Jingjing Ye, (unknown), (unknown)	4
3	Statistical Interpretation and Comparison of Waterfall Plots 2023 ·JCO Clinical Cancer Informatics ·Mo Huang, Cong Chen, Linda Sun	0
4	A promising biomarker adaptive Phase 2/3 design – Explained and expanded 2023 ·Contemporary Clinical Trials Communications ·Cong Chen, Linda Sun, Xuekui Zhang	1
5	Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned 2023 ·Therapeutic Innovation & Regulatory Science ·Sunhee Ro, (unknown), Qi Jiang, Xiaoyun Li, Rong Liu, (unknown), (unknown), Linda Sun, Jing Zhao	3
6	Framing the statistical criteria for accelerated approval of oncology drugs: A pathway for front runners 2023 ·Contemporary Clinical Trials ·Cong Chen, Linda Sun	3
7	Assessment of added activity of an antitumor agent 2022 ·Contemporary Clinical Trials ·Cong Chen, Linda Sun, Yixin Ren, Eric H. Rubin, David M. Weinstock, Emmett V. Schmidt	2
8	A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities 2021 ·Contemporary Clinical Trials ·Heng Zhou, Cong Chen, Linda Sun, Zhen Zeng	2
9	Bayesian optimal phase II clinical trial design with time‐to‐event endpoint 2020 ·Pharmaceutical Statistics ·Heng Zhou, Cong Chen, Linda Sun, Ying Yuan	15
10	Multiplicity for a group sequential trial with biomarker subpopulations 2020 ·Contemporary Clinical Trials ·Ting‐Yu Chen, Jing Zhao, Linda Sun, Keaven M. Anderson	6
11	Risk of Hypertension in Hemophilia Patients with a History of Inhibitors 2020 ·Blood ·(unknown), R. F. W. Barnes, Rebecca Kruse‐Jarres, Doris Quon, Shannon Jackson, Linda Sun, Annette von Drygalski	0
12	Advanced Utilization of Intermediate Endpoints for Making Optimized Cost-Effective Decisions in Seamless Phase II/III Oncology Trials 2019 ·Statistics in Biopharmaceutical Research ·Linda Sun, (unknown), Cong Chen, Jing Zhao	9
13	The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women 2016 ·Drug Metabolism and Disposition ·Stefan Zajic, Stefaan Rossenu, David Hreniuk, Filippos Kesisoglou, Jacqueline B. McCrea, Fang Liu, Linda Sun, Robert C. Witter, Donald R. Gauthier, (unknown), D. T. Joss, (unknown), R Stoltz, Julie A. Stone, S. Aubrey Stoch	6
14	232TiP KEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma 2015 ·Annals of Oncology ·Atsushi Ohtsu, Josep Tabernero, Yung‐Jue Bang, Charles S. Fuchs, Linda Sun, (unknown), (unknown), Minori Koshiji, Eric Van Cutsem	2
15	Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis 2015 ·Supportive Care in Cancer ·Karin Jordan, David Warr, Axel Hinke, Linda Sun, Paul J. Hesketh	22
16	P-106 Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study 2015 ·Annals of Oncology ·Atsushi Ohtsu, Josep Tabernero, Yung‐Jue Bang, Christiane Fuchs, Linda Sun, (unknown), (unknown), Minori Koshiji, Eric Van Cutsem	3
17	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study 2013 ·The Lancet Oncology ·Meletios Α. Dimopoulos, David S. Siegel, Sagar Lonial, Junyuan Qi, Roman Hájek, Thierry Façon, Laura Rosiñol, Catherine Williams, Hilary Blacklock, Hartmut Goldschmidt, Vânia Hungria, Andrew Spencer, Antonio Palumbo, Thorsten Graef, Joseph Eid, Jennifer Houp, Linda Sun, Scott Vuocolo, Kenneth C. Anderson	181
18	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial 2011 ·Blood ·Meletios Α. Dimopoulos, Sundar Jagannath, Sung‐Soo Yoon, David S. Siegel, Sagar Lonial, Roman Hájek, Thierry Façon, Laura Rosiñol, Hilary Blacklock, Hartmut Goldschmidt, Vânia Hungria, Andrew Spencer, Antonio Palumbo, Donna Reece, Thorsten Graef, Jennifer Houp, Linda Sun, Joseph Eid, Kenneth C. Anderson	32
19	Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma 2008 ·Annals of Oncology ·Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, Linda Sun, Justin L. Ricker, Huafeng Xie, Stanley R. Frankel, Sophia Randolph, Bruce D. Cheson	139
20	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma 2008 ·Leukemia & lymphoma ·Paul G. Richardson, Constantine Mitsiades, Kathleen Colson, E. M. O' Reilly, Laura McBride, Judy H. Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, (unknown), (unknown), Ivy Fearen, Kenneth C. Anderson, David S. Siegel	167

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact